IMMP
IMMUTEP Ltd
NASDAQ · Healthcare · Biotechnology · AU
$3.17
−0.94%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$3.17
From 52W high−95.02%
Volume6708.00
Market cap$23.36M
P/E (TTM)—
P/S (TTM)2.0x
Div yield—
Key dataOct 19, 2026
Open
$3.17
From 52W high
−95.02%
Volume
6708.00
Market cap
$23.36M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.4x
P/E (TTM)
—
RSI (14)
15.2
MomentumView details →
1D Return
−0.94%
YTD Return
−94.38%
SummaryUpdated Jun 1, 2026
Immutep Limited (NASDAQ:IMMP) is an Australian biotechnology company founded in 1987 and originally known as Prima BioMed Ltd before rebranding in November 2017. The company is headquartered in Sydney, Australia, and has been publicly traded since its IPO in April 2012. Immutep focuses on developing innovative immunotherapy treatments for cancer and autoimmune diseases, with its lead drug candidate currently in Phase IIb clinical trials for metastatic breast cancer treatment.
Similar companies
Latest newsMore news →
Immutep Limited received an A$856,669 cash rebate from the Australian Federal Government's R&D tax incentive program for eligible R&D expenditure incurred in the 2025 fiscal year.19d agoImmutep outlined a refocused development strategy for eftilagimod alfa (efti), concentrating future registration-directed work on head and neck squamous cell carcinoma (CPS below 1) and neoadjuvant soft tissue sarcoma, following a root cause analysis of the discontinued TACTI-004 study.39d ago